DGAP-News

Dr. med. Mariola Söhngen will be the new CEO of MOLOGEN AG (news with additional features) - Seite 2

the transformation process from a research-based biotech company to a
biopharmaceutical product company. We would like to extend our special
thanks to Dr. Schroff and Mr Petraß for their many years of service for the
good of the company and wish them all the best for the future."

Dr. Söhngen: "MOLOGEN has an impressive development pipeline"
"I look forward to working as part of a strong team. MOLOGEN has an
impressive development pipeline in the field of oncology and infectious
diseases. I consider the overall concept of enabling a patient's immune
system to effectively fight cancer and infections to be particularly
promising," comments Dr. Mariola Söhngen. After completing her medical
studies in 1987 (Dr. med. 1988), she went on to receive a Diploma in
Pharmaceutical Medicine (DGPharMed) and a Master of Business Communication.
Prior to founding PAION and taking up the post of CMO at the company, she
worked for various international pharmaceutical companies. Her
responsibilities not only included numerous clinical development projects,
but also project coordination, licensing and strategic project evaluation.
She also acted as an interface to marketing. In 1998, she founded her own
company, Bootcamp, which helps prepare young professionals for a career in
the health care industry. She founded PAION together with her husband, Dr.
Wolfgang Söhngen, in the year 2000, on the basis of a licensing agreement
for two biotechnological products with Schering AG.

MOLOGEN AG
MOLOGEN AG is a biotechnology company specialized in the research and
clinical development of cancer immunotherapies and DNA vaccines against
infectious diseases.

The cancer immunotherapy MGN1703 is the company's lead product and
best-in-class TLR9 agonist. It is currently developed for first-line
maintenance treatment of colorectal cancer (pivotal randomized trial) and
small cell lung cancer (randomized controlled trial). A second
clinical-stage product is MGN1601, a therapeutic vaccination for the
treatment of renal cancer. A phase I/II clinical study has already been
completed successfully.

For more information on the trials please visit www.clinicaltrials.gov.

With unique, patented technologies and innovative products, MOLOGEN is
pioneering immuno- therapies.

MOLOGEN AG is a publicly listed company, headquartered in Berlin. The
shares (ISIN DE0006637200) are listed in the Prime Standard of the German
Stock Exchange.

www.mologen.com

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |
German industrial association of biotechnology (DIB) | Association for